Newnorm (20% human normal immunoglobulin for SC) / Octapharma - LARVOL DELTA

NORM-01: Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases (clinicaltrials.gov) - P3 | N=50 | Active, not recruiting | Sponsor: Octapharma | Recruiting ➔ Active, not recruiting

Enrollment closed • Immunology • Primary Immunodeficiency

NORM-01: Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases (clinicaltrials.gov) - P3 | N=50 | Recruiting | Sponsor: Octapharma | Trial primary completion date: Jun 2025 ➔ Jun 2026

Trial primary completion date • Immunology • Primary Immunodeficiency

NORM-01: Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases (clinicaltrials.gov) - P3 | N=50 | Recruiting | Sponsor: Octapharma | Trial completion date: Jun 2025 ➔ Sep 2026

Trial completion date • Immunology • Primary Immunodeficiency